You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
Autoimmune diseases share a grim similarity with cancer: People's own cells become their enemies. But a study published online in Science reveals a happier parallel, suggesting that a therapy designed to harness the immune system to attack cancer cells may also cull the turncoat immune cells behind certain autoimmune diseases. The approach relies on chimeric antigen receptor T cells, or CAR T cells: immune cells genetically modified to home in on a desired target on cancer cells or—in this case—on rogue B cells, another immune cell type. The new study only gauged the CAR T cells' capabilities in the lab dish and in mouse models of pemphigus vulgaris, an autoimmune condition in which B cells secrete antibodies that attack a protein in skin and mucous membrane. But some scientists are already calling the approach, which specifically targets the errant B cells, a breakthrough.
